Summary.-Of 100 children and adolescents with lymphoblastic leukaemia (ALL) seen over a 6-year period, 25 developed clinically evident infiltration of the central nervous system (CNS), despite early treatment with cranial radiotherapy and intrathecal methotrexate.
IT HAS BEEN recognized for some time that the T-cell variety of lymphoblastic leukaemia (T ALL) carries a worse prognosis than non-T disease (Tsukimoto et al., 1976; Reid et al., 1977) and it has also been suggested to be frequently associated with meningeal (CNS) infiltration (Catovsky et al., 1974; Sallan et al., 1980) . However, the inextricable association between T ALL and high white counts, a well known adverse prognostic feature in any ALL, begs the question whether it is the cellular characteristics of T lymphoblasts or merely their numbers that possibly predispose them to infiltrate the CNS. We have attempted to answer this by studying an unselected group of ALL patients who happened to have a particularly high incidence of CNS involvement, and who also included a relatively large number of those with T-cell disease. without definite blasts in the CSF (one T and one non-T) as both subsequently developed overt meningeal infiltration.
The time to CNS relapse was measured as being from diagnosis to the first demonstration of CSF blasts or, in the two cases mentioned above, the onset of facial paralysis.
Statistical methods included x2 analysis (of the frequency of VIIth nerve palsy and hypothalamic infiltration), Student's t test (for the difference in mean times to CNS relapse of the T and non-T patients with CNS disease), life tables and logrank tests (of the frequency of CNS relapse and time to that event in all the T and non-T patients) and a multidimensional contingency table as described by Shaffer (1973) to assess the interdependence of T-cell markers, CNS disease and diagnostic white cell count (WCC).
RESULTS
One hundred patients with ALL presented during the study period including 17 (17%) with the features of T-cell disease. Twenty-five developed CNS involvement at some stage of their illness, of whom 9 (36%) had T-cell disease. The frequency of CNS relapse was much greater and also the time to that event much shorter in the T ALL patients when they were compared to the non-Ts (P < 0-001, see Figure) .
Of the 16 patients with non-T ALL who developed CNS disease, 4 had an associated unilateral facial palsy and 5 presented as the hypothalamic syndrome described by Greydanus et al. (1978) . Of the 9 T ALLs, however, 6 had an associated facial palsy and none had the hypothalamic syndrome. Thus, facial palsy is commoner (P < 0.05) and hypothalamic infiltration perhaps less common (0-1 <P > 0.05) in T compared to non-T ALL (see Table) .
There was no significant difference in the CSF blast cell count between the two groups, and this varied widely. Fits were uncommon as an associated feature and were seen in one patient from both groups. Although isolated CNS relapse (i.e. unassociated with disease activity elsewhere) was commoner in the non-T group (12 of 16 (75%) compared to 4 of 9 (44%); see Table) this did not approach statistical significance.
Considering the 3 parameters of T-cell markers, CNS disease and diagnostic WCC, their interdependence using a multidimensional contingency table showed that there was a strong relationship between WCC and T-cell markers (P < 0.01) and between T-cell markers and CNS disease (P < 0.02) but not between (West et al., 1972 (T and non-T) where it was seen that, while there was a strong interdependence between T-cell disease and a high WCC (P < 0*01) and also betweeni T-cell disease and CNS involvement (P < 0*02) there was not between CNS disease and WCC (P = 0 37).
Secondly, there are possibly some clinical differences between T and non-T CNS disease. Facial-nerve palsy seems to be more common in T-cell patients, a fact we have noted before (Lilleyman et al., 1979) and conversely, it may be that hypothalamic involvement is less common than in non-T disease, where it seems to occur as a later complication. These findings would suggest a significant difference in the migratory pattern of T and non-T lymphoblasts, suggesting a greater bulk of disease in santuary sites at the initiation of therapy.
Although the explanation of our findings is open to debate, the relevance of the observations is depressingly clear. Prophylactic therapy to the CNS, as currently used, is ineffective in most patients with T ALL. While it might be observed that systemic therapy is equally ineffective (Tsukimoto, 1976) 
